William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising potential of Rocket Pharmaceuticals’ RP-A601 treatment. The initial data from the Phase I study presented at the ASGCT conference demonstrated positive outcomes in terms of safety, efficacy, and transduction efficiency at the selected dose. This data supports the possibility of an accelerated approval pathway, as all patients showed increased PKP2 expression, which correlated with the localization of key proteins and early signs of disease modification.
Furthermore, the use of the same vector as Sarepta’s Elevidys, which has shown success, suggests a conservative approach with immunosuppression could be beneficial. The initial safety data is encouraging, and the early results set a new standard for PKP2-ACM efficacy. The anticipation of additional long-term follow-up data and insights into a potential registrational study further supports the Buy rating, indicating confidence in the company’s future prospects.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $55.00 price target.